Scarica l'app Stockscreener
219.72
4.96%
-11.46
Dopo l'orario di chiusura:
219.72
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$231.18
Aprire:
$231.31
Volume 24 ore:
1.66M
Relative Volume:
0.93
Capitalizzazione di mercato:
$29.40B
Reddito:
$4.29B
Utile/perdita netta:
$577.22M
Rapporto P/E:
52.21
EPS:
4.2086
Flusso di cassa netto:
$641.34M
1 W Prestazione:
-14.16%
1M Prestazione:
-17.83%
6M Prestazione:
-31.09%
1 anno Prestazione:
-52.34%
Intervallo 1D:
$219.40
$231.36
Intervallo di 1 settimana:
$219.40
$257.27
Portata 52W:
$197.81
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
219.72 | 34.25B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-07 | Ripresa | Oppenheimer | Outperform |
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Here's How Much $100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Benzinga
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN) - theglobeandmail.com
ALNY Maintains by JP Morgan -- Price Target Lowered to $369 - GuruFocus
Alnylam Pharmaceuticals, Carvana, MongoDB - TradingView
Cantor Fitzgerald reiterates Neutral rating on Alnylam stock By Investing.com - Investing.com Canada
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM - itemonline.com
Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside - nai500.com
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY) - Seeking Alpha
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - Yahoo Finance
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - Yahoo Finance
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - The Motley Fool
Form 4 Alnylam Pharmaceuticals Inc For: 27 September - Investing.com India
Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com - Investing.com Australia
Bernstein Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $376 - Moomoo
Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) - Seeking Alpha
Cambridge biotech co-founded by Alnylam founder Maraganore files for IPO - The Business Journals
Endpoints 11: Forget Alnylam or The Medicines Company. Corsera is Maraganore and Meanwell’s biggest bet - Endpoints News
The next Alnylam? RNAi biotech City Therapeutics files for IPO - Endpoints News
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price Today: $246.55 - Pluang
Alnylam Pharmaceuticals (ALNY) Short Interest & Short Float | Updated Sep 2026 $ALNY - MarketBeat
Alnylam Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Greenstreet Yvonne - moomoo.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates - Eastern Progress
ALNY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $455 - GuruFocus
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455 - moomoo.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with a 55% Upside Potential - DirectorsTalk Interviews
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook - Yahoo Finance
Will RNAi Market Growth Change Alnylam Stock's Narrative? - simplywall.st
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial - TradingView
Needham Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $357 - Moomoo
Alnylam Pharmaceuticals, Inc. RNAi Roundtable Call Transcript - gurufocus.com
Alnylam Pharmaceuticals (ALNY) Highlighted As An Oligonucleotide Therapeutics Leader Through 2035 - Simply Wall Street
Is Alnylam (ALNY) Quietly Repricing Its RNAi Risk Profile Amid Oligonucleotide Market Optimism? - finance.yahoo.com
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture - finance.yahoo.com
Alnylam Pharmaceuticals Inc (WBO:ALNY) Competitors 2026 - gurufocus.com
Alnylam Pharmaceuticals, Inc. at Morgan Stanley Global Healthcare Conference Transcript - gurufocus.com
Alnylam Pharmaceuticals (ALNY) Stock Analysis: A 49% Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
Alnylam Pharmaceuticals (ALNY) Gains Attention After Fresh RNAi Data, Is It 33% Undervalued? - simplywall.st
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Diluted earnings per share (diluted EPS) of Alnylam Pharmaceuticals, Inc – VIE:ALNY - TradingView
ETFs Investing in Alnylam Pharmaceuticals, Inc Stocks - TradingView
Why Alnylam Pharmaceuticals (ALNY) Stock Is Down Today - quiverquant.com
Best Biotech Stocks To Add to Your WatchlistSeptember 10th - MarketBeat
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined - Yahoo Finance
Understanding the Setup: (ALNY) and Scalable Risk - Stock Traders Daily
ALNY Maintained by Jefferies -- Price Target Raised to $260 - GuruFocus
Alnylam at Wells Fargo conference: TTR growth stays on track By Investing.com - Investing.com South Africa
Alnylam at Wells Fargo conference: TTR growth stays on track - Investing.com
Alnylam Pharmaceuticals, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Onpattro Market Analysis Reveals Trends in Changing Industry Demand - openPR.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A 39% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I | Director |
Jun 01 '26 |
Sale |
299.18 |
3,830 |
1,145,853 |
1,582 |
0.62%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):